LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 3 of 15: Cell count and relative growth within biological replicate 3. - Dataset (ID:20239)
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Replicate | Assay Well | Timepoint | Timepoint Unit | Total Cell Count Before Treatment | Total Cell Count After Treatment | Total Control Cell Count | Relative Cell Count | Relative Growth Rate After Treatment |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
BT-20 | Momelotinib | 1.11 | uM | LJP5 | 2 | P09 | 72 | hr | 1097 | 3138 | 3769 | 0.8325 | 0.7637 |
BT-20 | Momelotinib | 1.11 | uM | LJP5 | 3 | P09 | 72 | hr | 1097 | 3139 | 3769 | 0.8327 | 0.7641 |
BT-20 | Dasatinib | 1.11 | uM | LJP5 | 1 | D03 | 72 | hr | 1097 | 1253 | 3769 | 0.3324 | 0.0583 |
BT-20 | Dasatinib | 1.11 | uM | LJP5 | 2 | D03 | 72 | hr | 1097 | 1475 | 3769 | 0.3913 | 0.1414 |
BT-20 | Dasatinib | 1.11 | uM | LJP5 | 3 | D03 | 72 | hr | 1097 | 1471 | 3769 | 0.3902 | 0.1399 |
BT-20 | Dasatinib | 1.11 | uM | LJP6 | 1 | I03 | 72 | hr | 1097 | 1026 | 3769 | 0.2722 | -0.0267 |
BT-20 | Dasatinib | 1.11 | uM | LJP6 | 2 | I03 | 72 | hr | 1097 | 1141 | 3769 | 0.3027 | 0.0164 |
BT-20 | Dasatinib | 1.11 | uM | LJP6 | 3 | I03 | 72 | hr | 1097 | 991 | 3769 | 0.2629 | -0.0398 |
BT-20 | Dovitinib | 1.11 | uM | LJP5 | 1 | E21 | 72 | hr | 1097 | 1502 | 3769 | 0.3985 | 0.1515 |
BT-20 | Dovitinib | 1.11 | uM | LJP5 | 2 | E21 | 72 | hr | 1097 | 1521 | 3769 | 0.4035 | 0.1586 |
BT-20 | Dovitinib | 1.11 | uM | LJP5 | 3 | E21 | 72 | hr | 1097 | 1724 | 3769 | 0.4574 | 0.2345 |
BT-20 | Enzastaurin | 1.11 | uM | LJP5 | 1 | D15 | 72 | hr | 1097 | 3869 | 3769 | 1.0264 | 1.0372 |
BT-20 | Enzastaurin | 1.11 | uM | LJP5 | 2 | D15 | 72 | hr | 1097 | 4003 | 3769 | 1.0619 | 1.0874 |
BT-20 | Enzastaurin | 1.11 | uM | LJP5 | 3 | D15 | 72 | hr | 1097 | 3921 | 3769 | 1.0402 | 1.0567 |
BT-20 | Erlotinib | 1.11 | uM | LJP5 | 1 | M21 | 72 | hr | 1097 | 3381 | 3769 | 0.8969 | 0.8546 |
BT-20 | Erlotinib | 1.11 | uM | LJP5 | 2 | M21 | 72 | hr | 1097 | 3027 | 3769 | 0.8030 | 0.7221 |
BT-20 | Erlotinib | 1.11 | uM | LJP5 | 3 | M21 | 72 | hr | 1097 | 3089 | 3769 | 0.8195 | 0.7453 |
BT-20 | Foretinib | 1.11 | uM | LJP5 | 1 | H09 | 72 | hr | 1097 | 1353 | 3769 | 0.3589 | 0.0957 |
BT-20 | Foretinib | 1.11 | uM | LJP5 | 2 | H09 | 72 | hr | 1097 | 1309 | 3769 | 0.3473 | 0.0792 |
BT-20 | Foretinib | 1.11 | uM | LJP5 | 3 | H09 | 72 | hr | 1097 | 1147 | 3769 | 0.3043 | 0.0186 |
BT-20 | R406 | 1.11 | uM | LJP6 | 1 | C15 | 72 | hr | 1097 | 3427 | 3769 | 0.9091 | 0.8718 |
BT-20 | R406 | 1.11 | uM | LJP6 | 2 | C15 | 72 | hr | 1097 | 3448 | 3769 | 0.9147 | 0.8797 |
BT-20 | R406 | 1.11 | uM | LJP6 | 3 | C15 | 72 | hr | 1097 | 3376 | 3769 | 0.8956 | 0.8527 |
BT-20 | Pictilisib | 1.11 | uM | LJP6 | 1 | D21 | 72 | hr | 1097 | 1194 | 3769 | 0.3168 | 0.0362 |
BT-20 | Pictilisib | 1.11 | uM | LJP6 | 2 | D21 | 72 | hr | 1097 | 1277 | 3769 | 0.3388 | 0.0673 |